Intended for U.S. healthcare professionals only. For corporate information, please visit Mallinckrodt.com X

Clomipramine Hydrochloride Capsules, USP 25 mg

INDICATIONS AND USAGE

Clomipramine Hydrochloride Capsules USP is indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD).  The obsessions or compulsions must cause marked distress, be time-consuming, or significantly interfere with social or occupational functioning, in order to meet the DSM-III-R (circa 1989) diagnosis of OCD.

IMPORTANT RISK INFORMATION

Suicidality and Antidepressant Drugs

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of clomipramine hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide.  Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Clomipramine hydrochloride is not approved for use in pediatric patients except for patients with obsessive compulsive disorder (OCD).

CONTRAINDICATIONS

Clomipramine hydrochloride is contraindicated:

  • in patients with hypersensitivity to clomipramine hydrochlorideor other tricyclic antidepressants.
  • within 14 days of stopping an MAOI intended to treat psychiatric disorders.  The use of MAOIs intended to treat psychiatric disorders with clomipramine hydrochloride or within 14 days of stopping treatment with clomipramine hydrochloride is also contraindicated because of an increased risk of serotonin syndrome.
  • in patients who are being treated with linezolid or intravenous methylene blue because of an increased risk or serotonin syndrome.
  • during the acute recovery period after a myocardial infarction.

WARNINGS and PRECAUTIONS

  • All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.
  • Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers.
  • Prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder.
  • The development of serotonin syndrome has been reported with use of serotonin/norepinephrine reuptake inhibitors (SNRIs) and selective serotonin reuptake inhibitors (SSRIs), including clomipramine hydrochloride, alone but particularly with concomitant use of other serotonergic drugs (triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, busiprone, and St. John's Wort) or medications that impair metabolism of serotonin (e.g. MAOIs, including linezolid and intravenous methylene blue).
  • Seizures are a significant risk with use of clomipramine hydrochloride. Caution should be used in patents with a history of seizures or other predisposing factors e.g., brain damage, alcoholism, and other medications that may lower the seizure threshold.
  • Physicians should discuss with patients the risk of taking clomipramine hydrochloride while engaging in activities in which sudden loss of consciousness could result in serious injury to the patient or others, e.g., the operation of complex machinery, driving, swimming, and climbing.
  • Since depression is a commonly associated feature of OCD, the risk of suicide must be considered. Prescriptions for clomipramine hydrochloride should be written for the smallest quantity of capsules consistent with good patient management, in order to reduce the risk of overdose. Cardiovascular effects include modest orthostatic decreases in blood pressure and modest tachycardia (approximately 20% of patients). ECG abnormalities can be seen but were rarely associated with clinical symptoms.
  • A variety of neuropsychiatric signs and symptoms including delusions, hallucinations, psychotic episodes, confusion, and paranoia have been reported in patients treated with clomipramine hydrochloride.
  • Clomipramine hydrochloridemay precipitate an acute psychotic episode in patients with unrecognized schizophrenia.
  • Precipitation of hypomania and mania has been reported in patients receiving clomipramine hydrochloride for the treatment of affective disorders.  Activation of mania or hypomania has been reported in a small proportion of patients receiving other tricyclic antidepressants.
  • Clomipramine hydrochloridecan be associated with elevations in SGOT and SGPT (1-3% respectively) of potential clinical importance. Most were not associated with other clinical findings for hepatic injury.  Rare reports of more severe liver injury, some fatal, have been recorded in foreign postmarketing experience.
  • Leukopenia, agranulocytosis, thrombocytopenia, anemia and pancytopenia have been reported with the use of clomipramine hydrochloride.
  • Hyperthermia has been reported in patients receiving clomipramine hydrochloride. Most cases were in combination with other drugs, including neuroleptic agents.
  • Sexual dysfunction, including ejaculatory failure and impotence, is common in males.
  • Increases and decreases in weight can occur with use of clomipramine hydrochloride.
  • Concurrent administration of clomipramine hydrochloride with electroconvulsive therapy may increase the risks.
  • Prior to elective surgery with general anesthetics, therapy with clomipramine hydrochloride should be discontinued for as long as is clinically feasible, and the anesthetist should be advised.
  • Caution use in patients with the following concomitant Illnesses:
    • hyperthyroidism  or patients on hyperthyroid medications due to possible cardiac toxicity.
    • increased intraocular pressure, history of narrow-angle glaucoma or urinary retention due to anticholinergic properties of clomipramine hydrochloride.
    • tumors of the adrenal medulla (e.g. pheochromocytoma, neuroblastoma) in whom the drug may provoke hypertensive crises.
    • significant renal impairment.
     
  • Withdrawal symptoms have been reported in association with abrupt discontinuation of clomipramine hydrochloride. It is recommended that the dosage be tapered gradually and the patient monitored carefully during discontinuation.
  • Clomipramine hydrochloridemay exaggerate the effects of alcohol, barbiturates, or other CNS depressants.
  • Deaths may occur from overdosage with this class of drugs. 

ADVERSE REACTIONS 

  • Serious adverse reactions may include clinical worsening of depression and suicidal ideation; seizures; serotonin syndrome; neuropsychiatric signs and symptoms including delusions, hallucinations, psychotic episodes, confusion, and paranoia; precipitation of mania or hypomania; severe liver injury; hematologic changes including leukopenia, agranulocytosis, thrombocytopenia, anemia, and pancytopenia; and hyperthermia.
  • Common adverse reactions include gastrointestinal complaints, including dry mouth, constipation, nausea, dyspepsia, and anorexia; nervous system complaints, including somnolence, tremor, dizziness, nervousness, and myoclonus; genitourinary complaints, including changed libido, ejaculatory failure, impotence, and micturition disorder; and other miscellaneous complaints, including fatigue, sweating, increased appetite, weight gain, and visual changes. 

USE IN SPECIFIC POPULATIONS 

  • Safety and effectiveness in the pediatric population other than pediatric patients with OCD have not been established.'
  • Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.

Description Light Yellow Body/Orange Capsule
Identification Code Light yellow body imprinted in black with "M" in a box and orange cap imprinted in black with "25 mg"
Dosage Strength 25 mg
Compares To Anafranil™
Rating AB

ORDERING INFORMATION

NDC # Package Size Case Quantity
0406-8806-01 100 12

For additional information on Clomipramine Hydrochloride Capsules, USP 25 mg, call Customer Service at 1.800.325.8888 or Medical Information at 1.800.778.7898.